Immunic Capital Surpluse from 2010 to 2024

IMUX Stock  USD 1.11  0.02  1.77%   
Immunic Capital Surpluse yearly trend continues to be fairly stable with very little volatility. Capital Surpluse will likely drop to about 326.3 M in 2024. During the period from 2010 to 2024, Immunic Capital Surpluse regression line of annual values had r-squared of  0.30 and arithmetic mean of  298,770,698. View All Fundamentals
 
Capital Surpluse  
First Reported
2014-03-31
Previous Quarter
430 M
Current Value
431.8 M
Quarterly Volatility
91.8 M
 
Yuan Drop
 
Covid
Check Immunic financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunic's main balance sheet or income statement drivers, such as Depreciation And Amortization of 105.5 K, Interest Expense of 730.2 K or Other Operating Expenses of 54.8 M, as well as many indicators such as Price To Sales Ratio of 17.3 K, Dividend Yield of 0.0064 or PTB Ratio of 1.46. Immunic financial statements analysis is a perfect complement when working with Immunic Valuation or Volatility modules.
  
Check out the analysis of Immunic Correlation against competitors.
For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.

Latest Immunic's Capital Surpluse Growth Pattern

Below is the plot of the Capital Surpluse of Immunic over the last few years. It is Immunic's Capital Surpluse historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immunic's overall financial position and show how it may be relating to other accounts over time.
Capital Surpluse10 Years Trend
Slightly volatile
   Capital Surpluse   
349.119.266.324.427.492.326.-66%123%22%32%15%-34%100%
       Timeline  

Immunic Capital Surpluse Regression Statistics

Arithmetic Mean298,770,698
Geometric Mean285,978,939
Coefficient Of Variation29.17
Mean Deviation63,609,811
Median285,098,000
Standard Deviation87,150,290
Sample Variance7595.2T
Range372.5M
R-Value0.55
Mean Square Error5734.8T
R-Squared0.30
Significance0.03
Slope10,653,691
Total Sum of Squares106332.4T

Immunic Capital Surpluse History

2024326.3 M
2023492.1 M
2022427.9 M
2021324.2 M
2020266.8 M
2019119.6 M
2018349.8 M

About Immunic Financial Statements

Immunic investors use historical fundamental indicators, such as Immunic's Capital Surpluse, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immunic. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capital Surpluse492.1 M326.3 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Immunic Stock Analysis

When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.
News Freq…Investor S…